Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Dr Mark Hill, who has become a Fellow of the Society for Radiological Protection (FSRP).

Dr Mark Hill was awarded the honour of Fellow of the Society for Radiological Protection (FSRP) in recognition of his significant impact within the field of radiation protection.

Mark has over 30 years of experience in the field of radiation biology and physics. The main focus of his work relates to understanding the mechanisms behind how the spatial and temporal pattern of energy deposition by ionising radiation drives the subsequent biological response and ultimately the associated human health implications.

Alongside his research, Mark has been involved with a number of national and international committees, is Course Director of our MSc in Radiation Biology, lectures on the Annual Radiological Protection Summer School at University of Cambridge, and is a specialist radiobiology examiner on the First FRCR examination board for the Royal College of Radiologists. This year is also due to become a Member of the Committee on Medical Aspects of Radiation in the Environment (COMARE), which provides independent advice to all UK government departments and agencies.

Speaking of the award, Mark said “It is an honour to receive recognition from my peers for all the work I have done over the years”.

Similar stories

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.